A proposed federal rule would rewrite how patient release, caregiver dosing, and dose-below-the-limit decisions work across every NRC-licensed radiation program in the country. It hasn't been published yet, it isn't enforceable, but it's already worth your attention.

First: This Is a Proposal, Not the Current Rule

Nothing has changed yet. This is a proposed rule. It has not been published in the Federal Register. The public comment period (45 days once it does publish) hasn't started. NRC hasn't held its required public meeting yet. And even after a final rule is adopted, it wouldn't take effect until 30 days after that final publication.

If you're in Tennessee or Virginia, like most of our ARC member programs, there's an extra layer here too: both are Agreement States, meaning the state, not NRC directly, regulates most of our day-to-day radioactive material use. Even after NRC finalizes a rule like this, Tennessee and Virginia would each need to separately adopt compatible changes on their own timeline. Nothing in this document sets that timeline. So this is a "watch and prepare to comment" moment, not a "go update your procedures" moment.

What the NRC Is Trying to Change

The short version: NRC concluded that the science behind radiation protection hasn't really changed, but the implementation of ALARA has drifted. Their diagnosis is that "as low as reasonably achievable" gradually became "as low as achievable, period", with dose-reduction decisions made regardless of cost, benefit, or reasonableness. Their fix isn't to loosen the underlying dose limits. It's to retire the word ALARA entirely and replace it with what they're calling a "graded approach to dose management" which would be a tiered system of specific, determinate thresholds that trigger already-familiar requirements.

For occupational exposure, that looks like this: cross 100 mrem/year and worker training kicks in. Cross 500 mrem/year and individual monitoring kicks in. Cross 5 rem/year and you're at the actual limit, where the existing planned-special-exposure process, plus a brand-new, lighter-weight option called the "planned occupational dose limit extension", comes into play.

That new extension is worth knowing about if your program has ever had someone on staff bump up against their annual dose during a period of light PET/CT staffing with more patient per technologist or an interventional radiologist taking on a significant case load. It would let a worker draw on unused dose "banked" from the previous five years, up to twice the annual limit in a given year, without the heavier lifetime-tracking machinery that the existing planned-special-exposure process requires. It excludes lens dose and isn't available to minors or declared pregnant workers, but for everyone else, it could genuinely be a more practical tool than what exists today while keeping safety limits intact.

The Current Rule Versus the Proposal

What This Could Mean for Theranostics

This is where I want to slow down, because the patient-release rewrite is the single most consequential piece of this 180-page document for programs like ours.

Patient Release May Be the Most Immediate Medical-Use Issue

The current patient-release framework at 10 CFR 35.75 was built in 2002. At that time, the NRC was designing it around brachytherapy implants and single-administration therapies (think I-131 for thyroid disease). That made sense in 2002. It doesn't fully make sense anymore. Radiopharmaceutical therapy today, especially the therapies coalitions like ours are building programs around, now means a course of treatment: four to six cycles of Lu-177 DOTATATE or PSMA-617, spaced weeks apart, with the same patient and often the same caregiver present at every cycle.

The proposed rule seems to notice this and is perhaps an attempt to remedy those issues. The 0.5 rem release threshold for the general public doesn't change numerically, but the NRC is proposing to calculate it per administration regimen instead of per release. For a single I-131 ablation, that's a distinction without much difference. For a four-cycle Lu-177 regimen, it's a completely different calculation: the same 0.5 rem now covers the cumulative dose to household members across the entire course of treatment , not reset at each visit.

Alongside that, the NRC is proposing something genuinely useful: a formal regulatory definition of "caregiver," distinct from the general public, with its own higher dose allowance—up to 5 rem per regimen, the same as our own occupational limit, with informed written consent and risk education required whenever the caregiver's likely dose exceeds 0.5 rem. Anyone who has sat across the table from a spouse or parent explaining why they need to sleep in a separate room for a few days knows this distinction already exists in practice. It just hasn't existed in the regulation. Now it would.

There's also a real administrative win buried in here: the recordkeeping requirement at 35.2075 would shift from case-by-case dose-basis documentation to maintaining a single written release procedure for the life of the license. If your program has ever had to reconstruct the basis for a specific patient's release calculation two years after the fact, you might be able appreciate what this appears to be trying to solve.

What It Does (and Does Not) Mean for ALARA

I want to be direct about something, because I've already seen the phrase "NRC eliminates ALARA" floating around, and it's not quite right. What's being eliminated is the wording and the current implementation framework. The underlying obligation to keep doses below the limits, and don't let dose creep up just because you technically can, doesn't go away. It gets restated as a graded approach with specific numeric triggers instead of a subjective "reasonably achievable" judgment call. NRC is explicit that a program compliant with today's ALARA-based rules would remain compliant under the proposed framework without having to change a single practice. This is a relabeling and restructuring exercise layered on top of some genuinely new patient-release and dose-management provisions, not a wholesale abandonment of radiation protection principles. Which is something I was certainly concerned about having sat in on some of the public calls during development of this potential new guidance.

What Agreement State Programs Need to Know

For those of us in Tennessee, Virginia, or working across the ARC's Knoxville-to-Roanoke corridor, there's an extra step between "NRC finalizes this" and "this applies to my license." Both states are Agreement States, meaning they, not NRC, are the direct regulator for most byproduct-material use. The NRC's compatibility framework sorts every proposed change into categories, some would require Tennessee and Virginia to adopt essentially identical language; others leave states real discretion in how they implement the same objective. Notably, the caregiver provision at 35.75(b) is proposed to move into the more restrictive compatibility category, meaning states would eventually need to match NRC's caregiver framework closely rather than build their own variant. None of that has a timeline yet. It only starts once NRC finalizes a rule.

An Appalachian-community perspective: Smaller programs don't have the bandwidth to run two different playbooks, one for how the NRC does things and another for how our state does things. Regulatory consistency, clear written procedures instead of case-by-case documentation burden, and predictable caregiver-dose rules may not be abstract wins for us or just esoteric physics changes. They honestly could be the difference between a rural nuclear medicine department being able to run a multi-cycle therapy program at all, or deciding it's not worth the administrative overhead. That's exactly why I churned through this light bit of reading as soon as I saw it posted instead of waiting for someone else's summary.

What Your Program Should Do Now

Absolutely nothing operationally: your current procedures remain in force. But there's real value in getting ahead of this:

• Draft or refresh a written, procedure-based patient-release policy now. It's useful under today's rules and would put you ahead of the curve if this proposal is finalized substantially as written.
• Run the numbers on what per-regimen versus per-administration accounting would look like for your Lu-177 or Y-90 caseload. That's the single most useful thing you can bring to a public comment.
• Watch for Federal Register publication to start the formal 45-day comment clock, and watch for a revised Regulatory Guide 8.39, which will carry the actual worksheets and occupancy-factor assumptions this rule depends on.
• Don't wait on Tennessee or Virginia guidance as there isn't any yet, and there won't be until NRC finalizes something.

I'll be watching this one closely, and I'd genuinely like to hear what other programs think about the per-regimen accounting question in particular. It's the part of this proposal most likely to change how we practically run a multi-cycle therapy service.

What's your read on shifting patient-release accounting from per-release to per-regimen? Would it change how your program manages caregiver instructions across a multi-cycle course of treatment? I'd like to hear from you.